Major funding boost for neurotechnology innovation
Newcastle University, Newcastle upon Tyne Hospitals NHS Foundation Trust and ARIA have agreed a £6.2 million investment to expand clinical trials and develop treatments using neurotechnology at the National Centre for Neurotechnology and Neurorestoration in Newcastle. The funding will support specialist staff and expanded clinical facilities, helping move technologies such as brain-computer interfaces, neuromodulation and neuroprosthetics into patient care. The centre aims to increase access to innovative treatments for people with neurological conditions and support larger studies through NHS and international partnerships.
New £6.2 million investment to accelerate use of innovative neurotechnology in healthcare, including brain-computer interfaces and implants to restore movement and function.
Newcastle University, Newcastle upon Tyne Hospitals NHS Foundation Trust and the Advanced Research and Invention Agency (ARIA) have agreed a partnership to expand the use of cutting-edge brain and nervous system technologies in patients.
Through joint investment and shared priorities, the collaboration will mean more clinical trials and the development of new treatments at the National Centre for Neurotechnology and Neurorestoration (NCNN) at Newcastle Hospitals.
From discovery to patient care
The NHS NCNN, established in 2025, is the first in the UK dedicated to accelerating the use of pioneering neurotechnologies that interact with the brain and nervous system to help people experiencing significant difficulties with their physical or mental function.
This includes conditions such as Parkinson’s disease, epilepsy, motor neurone disease, spinal cord injury, and difficulties with memory, thinking or concentration.
Dr Luke Bashford, scientific director of the NCNN and researcher at Newcastle University, said: "The National Centre for Neurotechnology and Neurorestoration was created to enable and accelerate the delivery of clinical studies of neurotechnologies, advance research and development, and bridge the gap between scientific discovery and patient benefit. This investment will enable us to scale up this vital work.
"By working with people who have lived experience, innovators and policy makers, we can accelerate the development of safe and effective neurotechnologies, establish new treatments for neurological conditions and strengthen the UK's position as a global leader in this rapidly growing field."
The NCNN has world-class facilities for clinical trials and the investment will boost the team's work to research, develop, evaluate and use the latest neurotechnology in patients.
This is crucial because advances in technologies, such as brain-computer interfaces, neuromodulation and neuroprosthetics, are accelerating very quickly and the complexity of moving innovations into routine patient care needs unique expertise in a dedicated environment.
Mr Akbar Hussain, clinical director of the NCNN and consultant neurosurgeon at Newcastle Hospitals, said: "Neurological conditions are the leading cause of disability worldwide and can be life-changing, causing seizures, loss of movement and communication, issues with mood and difficulties with thinking.
“This funding will support a major boost in our capacity to use the latest neurotechnology to help people who have lost some or all of their normal ability.
"In the last couple of years, we've already seen some amazing successes through the use of innovative implant technology, in particular for patients who are living with Parkinson's disease, paralysis or severe pain.
"It's very exciting to think about the possibilities that will now be released through the early adoption of even more pioneering technology, to improve the abilities and independence of a wider range of people living with different neurological disorders."
Investment for growth
As the UK's flagship neurotechnology and neurorestoration centre, the unique NHS-university partnership brings together clinicians, researchers, industry partners and patients in a hospital environment, enabling innovative scientific discovery to be used in direct patient care, reaching the people who need it most.
The funding will grow a specialist workforce of clinical, technical and research staff, and allow the expansion of clinical facilities to meet the needs of neurotechnology innovators.
The centre also will facilitate the participation of more NHS organisations and research centres in neurotechnology studies, through training and multi-site projects, allowing a greater number of people to gain access to innovative treatments and technologies. In addition, international partnerships will support clinical studies on a larger scale.
Dr Jacques Carolan, programme director at ARIA, said: “There is an extraordinary amount of innovation in neurotechnology right now. The hard part is not simply inventing a new device — it is working out how to get it to the people who need it most. NCNN gives us a real-world place to do that.
“ARIA’s investment will help build the clinical and regulatory capability needed to translate the most promising neurotechnologies, both within our programmes and across the broader ecosystem, into real-world impact.”
https://www.ncl.ac.uk/press/articles/latest/2026/11/neurotechnologyandneurorestoration